|  | Tumor-related death | ||
---|---|---|---|---|
Variable | Categorisation | n | events | pa |
Clinico-pathologic data: | ||||
Age at diagnosis | ||||
 | <65 years | 44 | 20 | 0.0805 |
 | ≥65 years | 77 | 43 |  |
Gender | ||||
 | male | 64 | 31 | 0.4220 |
 | female | 59 | 34 |  |
Ann Arbor Stage | ||||
 | 1 | 19 | 6 | 0.0026 |
 | 2 | 37 | 16 |  |
 | 3 | 27 | 15 |  |
 | 4 | 39 | 27 |  |
International prognostic index | ||||
 | 0 | 2 | 0 | <0.0001 |
 | 1 | 46 | 16 |  |
 | 2 | 24 | 11 |  |
 | 3 | 25 | 20 |  |
 | 4 | 22 | 16 |  |
Extranodal involvement | ||||
 | no | 47 | 24 | 0.9997 |
 | yes | 70 | 36 |  |
Bulky disease | ||||
 | no | 73 | 36 | 0.3135 |
 | yes | 39 | 20 |  |
Serum levels of LDH at diagnosis | ||||
 | <300 U/l | 38 | 19 | 0.0133 |
 | ≥300 U/l | 54 | 31 |  |
Immunohistochemistry: | ||||
Mcm2 immunoreactivity | ||||
 | <40% | 52 | 21 | 0.0424 |
 | ≥40% | 36 | 22 |  |